Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization

Journal of Pharmacological Sciences

Volumn 115, Issue 1, 2011, Pages 63-68

  Sogawa, Yoshitaka ^a   Ohyama, Takao ^a   Maeda, Hiroaki ^a   Hirahara, Kazuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Chemotaxis; Cross desensitization; Formyl peptide receptor; Neutrophil

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 1; FORMYLPEPTIDE RECEPTOR 2; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; N (4 CHLOROPHENYL) N (5 ISOPROPYL 1 METHYL 3 OXO 2 PHENYL 2,3 DIHYDRO 1H PYRAZOL 4 YL)UREA; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METABOLIC INHIBITION; MIGRATION INHIBITION; NEUTROPHIL CHEMOTAXIS; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION;

EID: 79952376360     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10194FP     Document Type: Article

References (22)

1. Kobayashi SD, Voyich JM, Burlak C, DeLeo FR. Neutrophils in the innate immune response. Arch Immunol Ther Exp (Warsz). 2005;53:505-517. (Pubitemid 43035779)
2. Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195-S199. (Pubitemid 36458167)
3. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160:1532-1539.
4. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121:151S-155S.
5. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76: 301-314.
6. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev. 2009;61:119-161.
7. Sogawa Y, Shimizugawa A, Ohyama T, Maeda H, Hirahara K. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ ALX dual agonist. J Pharmacol Sci. 2009;111:317-321.
8. Burli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006;16:3713-3718. (Pubitemid 44137222)
9. Harada M, Habata Y, Hosoya M, Nishi K, Fujii R, Kobayashi M, et al. N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004;324: 255-261. (Pubitemid 39311487)
10. Didsbury JR, Uhing RJ, Tomhave E, Gerard C, Gerard N, Snyderman R. Receptor class desensitization of leukocyte chemoattractant receptors. Proc Natl Acad Sci U S A. 1991;88: 11564-11568. (Pubitemid 21916082)
11. Kitayama J, Carr MW, Roth SJ, Buccola J, Springer TA. Contrasting responses to multiple chemotactic stimuli in transendothelial migration: heterologous desensitization in neutrophils and augmentation of migration in eosinophils. J Immunol. 1997; 158:2340-2349. (Pubitemid 127470020)
12. Richardson RM, Ali H, Tomhave ED, Haribabu B, Snyderman R. Cross-desensitization of chemoattractant receptors occurs at multiple levels. Evidence for a role for inhibition of phospholipase C activity. J Biol Chem. 1995;270:27829-27833.
13. Tomhave ED, Richardson RM, Didsbury JR, Menard L, Snyderman R, Ali H. Cross-desensitization of receptors for peptide chemoattractants. Characterization of a new form of leukocyte regulation. J Immunol. 1994;153:3267-3275. (Pubitemid 24292553)
14. Ali H, Richardson RM, Haribabu B, Snyderman R. Chemoattractant receptor cross-desensitization. J Biol Chem. 1999;274: 6027-6030. (Pubitemid 29111002)
15. Sabroe I, Williams TJ, Hebert CA, Collins PD. Chemoattractant cross-desensitization of the human neutrophil IL-8 receptor involves receptor internalization and differential receptor subtype regulation. J Immunol. 1997;158:1361-1369. (Pubitemid 127469962)
16. Deng X, Ueda H, Su SB, Gong W, Dunlop NM, Gao JL, et al. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/ LXA4R. Blood. 1999;94:1165-1173. (Pubitemid 29380396)
17. Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, et al. The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood. 2001;97: 2941-2947.
18. Shen W, Proost P, Li B, Gong W, Le Y, Sargeant R, et al. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. Biochem Biophys Res Commun. 2000;272:276-283. (Pubitemid 30444934)
19. Howell LL, Kimmel HL. Monoamine transporters and psycho-stimulant addiction. Biochem Pharmacol. 2008;75:196-217.
20. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37. (Pubitemid 38161221)
21. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007;119:1055-1062. (Pubitemid 46654167)
22. Sogawa Y, Ohyama T, Maeda H, Hirahara K. Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: Indication of cross-desensitization in vivo. Immunology. In press. doi: 10.1111/j.1365-2567.2010.03367.x.